Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd (ASPIRA) last traded at ₹86.5, a market capitalisation of ₹89 crore, on a P/E of 37.1. Over the past 52 weeks the stock has ranged between ₹49 and ₹136. Aspira Pathlab & Diagnostics Ltd last reported results for the quarter ended Jun 2025, with sales of ₹5.25 crore and net profit of ₹0.42 crore. Figures are as of 25 Aug 2026 and are not real time.
Aspira Pathlab & Diagnostics Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Aspira Pathlab & Diagnostics Ltd quarterly results
In the quarter ended Jun 2025, sales were ₹5.25 cr, up 13.1% from ₹4.64 cr a year earlier. Net profit was ₹0.42 cr, up 740.0% year on year.
| ₹ crore | Jun 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 2.6 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 |
| Expenses | 3.02 | 4.03 | 4.38 | 4.91 | 4.81 | 4.86 | 4.57 |
| Operating profit | -0.42 | -0.21 | 0.26 | 1.27 | 0.6 | 0.92 | 0.68 |
| OPM % | -16.15% | -5.50% | 5.60% | 20.55% | 11.09% | 15.92% | 12.95% |
| Other income | 0.1 | 0.08 | 0.16 | 0.08 | 0.09 | 0.13 | 0.11 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.39 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 |
| Profit before tax | -0.71 | -0.51 | 0.04 | 0.99 | 0.3 | 0.68 | 0.42 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.72 | -0.5 | 0.05 | 0.99 | 0.31 | 0.68 | 0.42 |
| EPS (₹) | -0.70 | -0.49 | 0.05 | 0.96 | 0.30 | 0.66 | 0.41 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aspira Pathlab & Diagnostics Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Sales | 13.2 | 22 | 22.62 |
| Operating profit | -1.18 | 3.51 | 3.47 |
| OPM % | -8.94% | 15.95% | 15.34% |
| Net profit | -2.67 | 2.02 | 2.4 |
| EPS (₹) | -2.59 | 1.96 | 2.33 |
TTM is the trailing twelve months to the most recent quarter.
Aspira Pathlab & Diagnostics Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 67%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 177%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 24%
- 1 Year
- 44%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 33%
Aspira Pathlab & Diagnostics Ltd shareholding pattern
Promoters held 46.58% at Jun 2026, up from 18.39% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 18.55% | 18.55% | 18.39% | 18.39% | 18.39% | 18.39% | 18.39% | 46.58% |
| Public | 81.46% | 81.46% | 81.62% | 81.62% | 81.61% | 81.61% | 81.61% | 53.41% |
| No. of shareholders | 1,706 | 1,593 | 1,741 | 1,770 | 1,755 | 1,784 | 1,769 | 1,620 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Aspira Pathlab & Diagnostics Ltd corporate filings
- Newspaper Publication for the Financial Result as on 30 June 2026Company Updatemedium impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has released its unaudited standalone financial…
Read the full analysis - Outcome of Board Meeting held on 12th August 2026Board Meetinghigh impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited reported a net loss of 3.77 lakh for the quarter…
Read the full analysis - Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1.Unaudited Financial ....Board Meetinghigh impact
Cruxal's analysis: Aspira Pathlab & Diagnostics Limited has scheduled a board meeting for August 12, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Aspira Pathlab & Diagnostics Ltd
Cruxal reads every Aspira Pathlab & Diagnostics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.